Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging
Denise P. Muñoz, Steven M. Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam M. Freund, Francis Rodier, Jennifer D. Wu, Pierre-Yves Desprez, David H. Raulet, Peter S. Nelson, Laura J. van ’t Veer, Judith Campisi, Jean-Philippe Coppé
Denise P. Muñoz, Steven M. Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam M. Freund, Francis Rodier, Jennifer D. Wu, Pierre-Yves Desprez, David H. Raulet, Peter S. Nelson, Laura J. van ’t Veer, Judith Campisi, Jean-Philippe Coppé
View: Text | PDF
Research Article Aging Oncology

Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging

  • Text
  • PDF
Abstract

Cellular senescence is a tumor-suppressive mechanism that can paradoxically contribute to aging pathologies. Despite evidence of immune clearance in mouse models, it is not known how senescent cells (SnCs) persist and accumulate with age or in tumors in individuals. Here, we identify cooperative mechanisms that orchestrate the immunoevasion and persistence of normal and cancer human SnCs through extracellular targeting of natural killer receptor signaling. Damaged SnCs avoided immune recognition through MMP-dependent shedding of NKG2D ligands reinforced via paracrine suppression of NKG2D receptor–mediated immunosurveillance. These coordinated immunoediting processes were evident in residual, drug-resistant tumors from cohorts of more than 700 prostate and breast cancer patients treated with senescence-inducing genotoxic chemotherapies. Unlike in mice, these reversible senescence subversion mechanisms were independent of p53/p16 and exacerbated in oncogenic RAS-induced senescence. Critically, the p16INK4A tumor suppressor could disengage the senescence growth arrest from the damage-associated immune senescence program, which was manifest in benign nevus lesions, where indolent SnCs accumulated over time and preserved a non-proinflammatory tissue microenvironment maintaining NKG2D-mediated immunosurveillance. Our study shows how subpopulations of SnCs elude immunosurveillance and reveals potential secretome-targeted therapeutic strategies to selectively eliminate — and restore the clearance of — the detrimental SnCs that actively persist after chemotherapy and accumulate at sites of aging pathologies.

Authors

Denise P. Muñoz, Steven M. Yannone, Anneleen Daemen, Yu Sun, Funda Vakar-Lopez, Misako Kawahara, Adam M. Freund, Francis Rodier, Jennifer D. Wu, Pierre-Yves Desprez, David H. Raulet, Peter S. Nelson, Laura J. van ’t Veer, Judith Campisi, Jean-Philippe Coppé

×

Figure 6

High levels of MMPs in persistent SnCs are responsible for NKG2D ligand shedding and cause SnCs to evade immune detection, but can be targeted to rescue the clearance of residual SnCs, regardless of their p53/p16 status.

Options: View larger image (or click on image) Download as PowerPoint
High levels of MMPs in persistent SnCs are responsible for NKG2D ligand ...
(A) Soluble MICA quantified by ELISA in media from senescent WI-38 cells treated with increasing concentrations of GM6001 or mock treated (DMSO). (B) Immunofluorescence detection of NKG2D ligands after mock (top) or GM6001 (bottom) treatment of XRA WI-38 cells. Original magnification, ×40. (C) Survival assessed by LDH release in WI-38 and IMR-90 SnCs treated with GM6001 prior to 12 hour coculture with IL-2–preactivated PBMCs or NK cells (effector/target ratio, 1:3). (D) Percent survival assessed by number of SnCs remaining after coculture with PBMCs for 20 days, with 2 rounds of PBMCs separated by 10 days, with either mock or GM6001 treatment before the second round of PBMC addition. In A, C, and D, box plot length: 25% and 75% of data; centerline: median; whiskers: 25% – (or 75% +) 1.5 × IQR; dots: outliers; color bars: average. (E) Schematic summary: p53/p16-independent clearance rescue of persistent SnCs via coordinated targeting of MMP/NKG2D ligand signaling. Stabilizers of cell surface presentation of NKG2D ligands, such as extracellular protease inhibitors, are effective senolytics that restore clearance.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts